StartBHC • NYSE
add
Bausch Health Companies Inc
5,53 $
Efter lukketid:(0,00 %)0,00
5,53 $
Lukket: 14. aug., 16.01.43 GMT-4 · USD · NYSE · Ansvarsfraskrivelse
Seneste lukkekurs
5,48 $
Dagsinterval
5,46 $ - 5,55 $
Årsinterval
3,96 $ - 11,46 $
Markedsværdi
1,99 mia. USD
Gns. volumen
5,20 mio.
P/E-værdi
-
Udbytteprocent
-
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Indtægt | 2,40 mia. | 10,89 % |
Driftsudgifter | 1,26 mia. | 10,91 % |
Nettoindtægt | 10,00 mio. | -61,54 % |
Overskudsgrad | 0,42 | -65,00 % |
Earnings per share | 0,98 | 21,83 % |
EBITDA | 741,00 mio. | 6,47 % |
Effektiv afgiftssats | 102,08 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 595,00 mio. | 2,76 % |
Samlede aktiver | 26,50 mia. | 3,89 % |
Samlede passiver | 26,72 mia. | 5,91 % |
Samlet egenkapital | -227,00 mio. | — |
Shares outstanding | 367,10 mio. | — |
Kurs/indre værdi | -1,71 | — |
Afkast af aktiver | 3,96 % | — |
Afkast af kapital | 4,88 % | — |
Pengestrøm
Nettoændring i likviditet
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 10,00 mio. | -61,54 % |
Pengestrøm fra drift | 380,00 mio. | 84,47 % |
Pengestrøm fra investering | -79,00 mio. | -163,33 % |
Pengestrøm fra finansiering | -424,00 mio. | -253,33 % |
Nettoændring i likviditet | -132,00 mio. | -331,58 % |
Fri pengestrøm | 431,62 mio. | 72,13 % |
Om
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
Administrerende direktør
Grundlagt
1959
Hovedkvarter
Website
Ansatte
20.270